ASHP Therapeutic position statement on the cessation of tobacco use

American Journal of Health-System Pharmacy

Volumn 66, Issue 3, 2009, Pages 291-307

  Hudmon, Karen Suchanek ^a   Corelli, Robin L ^b,c  

^a PURDUE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c AMERICAN SOCIETY OF HEALTH SYSTEM PHARMACISTS   (United States)

Author keywords

American society of health system pharmacists; Drug interactions; Education; Guidelines; Health professions; Patient care; Patient information; Sales; Smoking; Tobacco; Toxicity

Indexed keywords

AMFEBUTAMONE; CLONIDINE; NICOTINE; NICOTINE GUM; NICOTINE PATCH; NORTRIPTYLINE; PLACEBO; TOBACCO SMOKE; VARENICLINE;

ABNORMAL DREAMING; AGITATION; BEHAVIOR CHANGE; BEHAVIOR DISORDER; BEHAVIOR THERAPY; BURN; BURNING SENSATION; CIGARETTE SMOKING; CLINICAL TRIAL; CONSTIPATION; COUH; DEPRESSION; DIZZINESS; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DYSPEPSIA; EPIPHORA; ERYTHEMA; EVIDENCE BASED MEDICINE; FLATULENCE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HEALTH EDUCATION; HEALTH PROMOTION; HEARTBURN; HICCUP; HUMAN; HYPERSALIVATION; INSOMNIA; LOCAL SKIN REACTION; MEDICAL INFORMATION SYSTEM; MEDICAL SOCIETY; MORNING DOSAGE; MOUTH DISCOMFORT; MOUTH IRRITATION; MOUTH PAIN; NAUSEA; NERVOUSNESS; NICOTINE REPLACEMENT THERAPY; PATIENT COUNSELING; PHARMACY; PREVALENCE; PRIORITY JOURNAL; PRURITUS; REVIEW; SIDE EFFECT; SLEEP DISORDER; SMOKING CESSATION; SNEEZING; SUICIDAL IDEATION; TASTE DISORDER; THROAT IRRITATION; TOBACCO DEPENDENCE; VIVID DREAM; VOMITING; XEROSTOMIA;

EID: 60549118169     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070303     Document Type: Review

References (74)

1. The health consequences of smoking: cancer. A report of the Surgeon General. http://profiles.nlm.nih.gOv/NN/B/C/D/W/-/nnbcdw.pdf (accessed 2008 Jul 16).
2. Centers for Disease Control and Prevention. Annual smoking- attributable mortality, years of potential life lost, and productivity losses-United States, 1997-2001. MMWR. 2005; 54:625-8.
3. U.S. Department of Health and Human Services. 2006 Surgeon General's report: the health consequences of involuntary exposure to tobacco smoke, www.cdc.gov/tobacco/data-statistics/sgr/sgr-2006/index.htm (accessed 2008 Jul 16).
4. Doll R, Peto R, Boreham J et al. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ. 2004; 328:1519.
5. Centers for Disease Control and Prevention. Cigarette smoking among adults-United States, 2000. MMWR. 2002; 51:642-5.
6. Centers for Disease Control and Prevention. Cigarette smoking among adults-United States, 2006. MMWR. 2007; 56: 1157-61.
7. Lasser K, Boyd JW, Woolhandler S et al. Smoking and mental illness: a population-based prevalence study. JAMA. 2000;284:2606-10.
8. Centers for Disease Control and Prevention. State-specific prevalence of cigarette smoking among adults and quitting among persons aged 18-35 years-United States, 2006. MMWR. 2007; 56: 993-6.
9. U.S. Department of Health and Human Services. 1994 Surgeon General's report-preventing tobacco use among young people, www.cdc.gov/tobacco/data- statistics/sgr/sgr-1994/index.htm(accessed 2008 Aug 13).
10. U.S. Department of Health and Human Services. Healthy People 2010. Vol. I and II. www.healthypeople.gov/publications/ (accessed 2008 Jul 16).
11. Johnston LD, O'Malley PM, Bachman JG et al. Teen smoking resumes decline. www.monitoringthefuture.org/data/07data.html#2007data-cigs (accessed 2008 May 21).
12. U.S. Department of Agriculture. Tobacco outlook. Report TBS-263. http://sda.mannlib.cornell.edu/usda/ers/ TBS//2000s/2007/TBS-10-24-2007.pdf (accessed 2008 Aug 13).
13. Substance Abuse and Mental Health Services Administration Offices of Applied Studies (2008). Results from the 2007 National Survey on Drug Use and Health: National findings (DHHS publication no. SMA 08-4343). Rockville, MD.
14. Henningfield JE, Fant RV, Radzius A et al. Nicotine concentration, smoke pH and whole tobacco aqueous pH of some cigar brands and types popular in the United States. Nicotine Tob Res. 1999; 1:163-8.
15. Connolly GN, Alpert HR, Wayne GF et al. Trends in nicotine yield in smoke and its relationship with design characteristics among popular US cigarette brands, 1997-2005. Tob Control. 2007; 16:e5.
16. Ebbert JO, Carr AB, Dale LC. Smokeless tobacco: an emerging addiction. Med Clin North Am. 2004; 88:1593-605.
17. Centers for Disease Control and Prevention. Annual smoking-attributable mortality, years of potential life lost, and economic costs-United States, 1995-1999. MMWR. 2002; 51:300-3.
18. Best practices for comprehensive tobacco control programs-2007. Atlanta: Centers for Disease Control and Prevention; 2007.
19. Task Force on Community Preventive Services. The guide to community preventive services: tobacco use prevention and control. Am J Prev Med. 2001; 20(suppl 2):l-88.
20. U.S. Department of Health and Human Services. The health consequences of smoking: nicotine addiction: a report of the Surgeon General. htt:p://profiles.nlm.nih.gov/NN/B/B/Z/D/-/nnbbzd.pdf (accessed 2008 Jul 16).
21. Benowitz NL. Clinical pharmacology of nicotine: implications for understanding, preventing and treating tobacco addition. Clin Pharm Ther. 2008; 83:531-41.
22. Hughes JR, Gust SW, Skoog K et al. Symptoms of tobacco withdrawal: a replication and extension. Arch Gen Psychiatry. 1991; 48:52-9.
23. Hughes JR. Effects of abstinence from tobacco: valid symptoms and time course. Nicotine Tob Res. 2007; 9:315-327.
24. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition. Washington, DC: American Psychiatric Publising; 1994.
25. Benowitz NL. Cigarette smoking and nicotine addiction. Med Clin North Am. 1992; 76:415-37.
26. Hatsukami DK, Gust SW, Keenan RM. Physiologic and subjective changes from smokeless tobacco withdrawal. Clin Pharmacol Ther. 1987; 41:103-7.
27. Centers for Disease Control and Prevention. U.S. 2004 Surgeon General's report-the health consequences of smoking, www.cdc.gov/tobacco/data-statistics/ sgr/sgr-2004/index.htm(accessed 2008 Jul 16).
28. Henley SJ, Thun MJ, Connell C et al. Two large prospective studies of mortality among men who use snuff or chewing tobacco (United States). Cancer Causes Control. 2005; 16:347-58.
29. Hergens MP, Ahlbom A, Andersson T et al. Swedish moist snuff and myocardial infarction among men. Epidemiology. 2005; 16:12-16.
30. Gupta R, Gurm H, Bartholomew JR. Smokeless tobacco and cardiovascular risk. Arch Intern Med. 2004; 164:1845-9.
31. Henley SJ, Connell CJ, Richter P et al. Tobacco-related disease mortality among men who switched from cigarettes to spit tobacco. Tob Control. 2007; 16:22-8.
32. California Environmental Protection Agency. Proposed identification of environmental tobacco smoke as a toxic air contaminant: executive summary, www. arb.ca.gov/regact/ets2006/ets2006.htm (accessed 2008 Oct 1).
33. Kroon LA. Drug interactions with smoking. Am J Health-Syst Pharm. 2007; 64: 1917-21.
34. Zevin S, Benowitz NL. Drug interactions with tobacco smoking. Clin Pharmacokinet. 1999; 36:425-38.
35. U.S. Department of Health and Human Services. The benefits of smoking cessation. A report of the surgeon general (DHHS publication no. CDC 90-8416). U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention and Health Promotion, Office on Smoking and Health. 1990.
36. Hazelden Foundation. Survey on current and former smokers-1998. www.hazelden.org/web/public/smokersl998.page (accessed 2008 Aug 13.).
37. Fiore MC, Jaen CR, Baker TB et al. Treating tobacco use and dependence-2008 update. Clinical practice guideline, www.surgeongeneral.gov/ tobacco/treating-tobacco-use08.pdf (accessed 2008 Jul 16).
38. Stead L, Perera R, Lancaster T. Telephone counselling for smoking cessation. Cochrane Database Syst Rev. 2006; 3:CD002850.
39. Ossip-Klein DJ, Mcintosh S. Quitlines in North America: evidence base and applications. Am J Med Sci. 2003; 326:201-5.
40. Zhu SH, Anderson CM, Tedeschi GJ et al. Evidence of real-world effectiveness of a telephone quitline for smokers. N Engl f Med. 2002; 347:1087-93.
41. Lichtenstein E, Glasgow RE, Lando HA et al. Telephone counseling for smoking cessation: rationales and meta-analytic review of evidence. Health Educ Res. 1996; 11:243-57.
42. Hopkins DP, Briss PA, Ricard CJ et al. Reviews of evidence regarding interventions to reduce tobacco use and exposure to environmental tobacco smoke. Am J Prev Med. 2001; 20(2, suppl):16-66.
43. Rx for Change: clinician-assisted tobacco cessation, http://rxforchange. ucsf.edu (accessed 2008 Oct 1).
44. Benowitz NL. Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. Prog Cardiovasc Dis. 2003; 46:91-111.
45. Working Group for the Study of Transdermal Nicotine in Patients with Coronary Artery Disease. Nicotine replacement therapy for patients with coronary artery disease. Arch Intern Med. 1994; 154: 989-95.
46. Joseph AM, Norman SM, Ferry LH et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med. 1996; 335:1792-8.
47. Tzivoni D, Keren A, Meyler S et al. Cardiovascular safety of transdermal nicotine patches in patients with coronary artery disease who try to quit smoking. Cardiovasc Drugs Ther. 1998; 12:239-44.
48. Hubbard R, Lewis S, Smith C et al. Use of nicotine replacement therapy and the risk of acute myocardial infarction, stroke, and death. Tob Control. 2005; 14:416-21.
49. McRobbie H, Hajek P. Nicotine replacement therapy in patients with cardiovascular disease: guidelines for health professionals. Addiction. 2001; 96:1547-51.
50. Joseph AM, Fu SS. Safety issues in pharmacotherapy for smoking in patients with cardiovascular disease. Prog Cardiovasc Dis. 2003; 45:429-41.
51. Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J Am Coll Cardiol. 1997; 29:1422-31.
52. Meine TJ, Patel MR, Washam JB et al. Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes. Am J Cardiol. 2005; 95:976-8.
53. Benowitz NL, Dempsey DA. Pharmacotherapy for smoking cessation during pregnancy. Nicotine Tob Res. 2004;6(Suppl2):S189-202.
54. Ascher JA, Cole JO, Colin J et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry. 1995; 56:395-401.
55. Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther. Oct 2000; 295:321-7.
56. Hayford KE, Patten CA, Rummans TA et al. Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. Br J Psychiatry. 1999; 174:173 -8.
57. Hughes J, Stead L, Lancaster T. Antide- pressantsfor smoking cessation. Cochrane Database Syst Rev. 2007(1):CD000031.
58. Zyban (bupropion hydrochloride) package insert. Research Triangle Park, NC: GlaxoSmithKline, Inc.; 2007 Aug.
59. Dunner DL, Zisook S, Billow AA et al. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J Clin Psychiatry. 1998; 59:366-73.
60. Foulds J The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline. Int J Clin Pract. May 2006; 60:571-6.
61. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2008(3):CD006103.
62. Chantix (varenicline) package insert. New York: Pfizer, Inc.; 2008 May.
63. Food and Drug Administration. Varenicline information, www.fda.gov/cder/drug/infopage/varenicline/default.htm(accessed 2008 May 22).
64. Bars MP, Banauch GI, Appel D et al. Tobacco Free With FDNY: the New York City Fire Department World Trade Center Tobacco Cessation Study. Chest. 2006; 129:979-87.
65. State-specific prevalence of current cigarette smoking among adults and second hand smoke rules and policies in homes and workplaces, United States, 2005. MMWR. 2006; 55:1148-51.
66. Fichtenberg CM, Glantz SA. Effect of smoke-free workplaces on smoking behaviour: systematic review. BMJ. 2002; 325:188.
67. Ong MK, Glantz SA. Free nicotine replacement therapy programs vs implementing smoke-free workplaces: a cost- effectiveness comparison. Am J Public Health. 2005; 95:969-75.
68. American Nonsmokers' Rights Foundation. States, commonwealths, and municipalities with 100% smokefree laws in workplaces, restaurants or bars. www.no-smoke.org/pdf/100ordlist.pdf (accessed 2008 Aug 13).
69. Ong MK, Glantz SA. Cardiovascular health and economic effects of smoke- free workplaces. Am J Med. 2004; 117:32-8.
70. American Pharmacists Association. Code of ethics for pharmacists. http://www.pharmacist.com/AM/ Template.cfm?Section=Code-of-Ethics-for- Pharmacists&Template=/CM/HTMLDisplay.cfm&ContentID = 5420 (accessed 2008 Aug 13).
71. American Society of Health-System Pharmacists. ASHP policy position 0713: tobacco and tobacco products. http://www.ashp.org/s-ashp/docs/files/BP07/HR- Positions.pdf (accessed 2008 Aug 13).
72. Davis RM. Tobacco sales in pharmacies: mixing good drugs and bad drugs. Tob Control. 1992; 1:84-96.
73. Hudmon KS, Prokhorov AV, Corelli RL. Tobacco cessation counseling: pharmacists' opinions and practices. Patient Educ Couns. 2006; 61:152-60.
74. Hudmon KS, Corelli RL, Fenlon CM et al. Pharmacy student perceptions of tobacco sales in pharmacies and suggested methods for promoting tobacco-free experiential sites. Am f Pharm Educ. 2006; 70:75.